Trial Profile
PHASE 1B STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND EITHER LETROZOLE OR FULVESTRANT IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED/RECURRENT BREAST CANCER (MBC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Gedatolisib (Primary) ; Letrozole (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celcuity
- 09 Dec 2022 According to Celcuity media release, data from this study were presented during a Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium (SABCS).
- 09 Dec 2022 Results published in the Celcuity Media Release
- 22 Nov 2022 According to Celcuity media release, Arm D results provide a strong rationale for phase 3 trial.